Company intelligence / Profile preview

Laurus Therapeutics

Visakhapatnam, Andhra Pradesh, India

Ownership: Private
Employees: ~6000
Development stage: Other

Overview

Laurus Labs is commercially successful in APIs, especially antiretrovirals; growing CDMO/CMO business; Laurus Bio supplies recombinant proteins globally; CAR-T cell therapy (NexCAR19) is in the clinical stage and aims to be India’s first approved CART therapy for blood cancers.

Therapeutic areas: CardiovascularImmunologyGastroenterologyInfectious DiseasesOncology
Modalities: Small moleculeBiologicCell therapyGene therapyRecombinant proteinEnzymeGrowth factorAnimal-origin-free recombinant protein
Industry: Biotech

Partnerships

Willow Biosciences (bioprocess development collaboration)ImmunoACT (CAR-T development partnership/investment)IIT Kanpur (academic collaboration for gene therapy)KRKA (Slovenian JV for formulations in Europe)

Beyond the preview

Go deeper on Laurus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laurus Therapeutics.

Explore the full profile